These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

687 related items for PubMed ID: 21728914

  • 21. Retrospective analysis of real-world efficacy of angiotensin receptor blockers versus other classes of antihypertensive agents in blood pressure management.
    Petrella R, Michailidis P.
    Clin Ther; 2011 Sep; 33(9):1190-203. PubMed ID: 21885126
    [Abstract] [Full Text] [Related]

  • 22. The lack of benefit of a combination of an angiotensin receptor blocker and calcium channel blocker on contrast-induced nephropathy in patients with chronic kidney disease.
    Oguzhan N, Cilan H, Sipahioglu M, Unal A, Kocyigit I, Kavuncuoglu F, Arikan T, Akpek M, Elcik D, Sahin O, Gulme E, Pala C, Tokgoz B, Utas C, Oguzhan A, Oymak O.
    Ren Fail; 2013 Sep; 35(4):434-9. PubMed ID: 23413781
    [Abstract] [Full Text] [Related]

  • 23. Copayment level, treatment persistence, and healthcare utilization in hypertension patients treated with single-pill combination therapy.
    Yang W, Kahler KH, Fellers T, Orloff J, Chang J, Bensimon AG, Wu EQ, Fan CP, Yu AP.
    J Med Econ; 2011 Sep; 14(3):267-78. PubMed ID: 21446895
    [Abstract] [Full Text] [Related]

  • 24. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
    Ruilope LM, Malacco E, Khder Y, Kandra A, Bönner G, Heintz D.
    Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
    [Abstract] [Full Text] [Related]

  • 25. Ambulatory blood pressure response to triple therapy with an angiotensin-receptor blocker (ARB), calcium-channel blocker (CCB), and HCTZ versus dual therapy with an ARB and HCTZ.
    Duprez D, Ferdinand K, Purkayastha D, Samuel R, Wright R.
    Vasc Health Risk Manag; 2011 May; 7():701-8. PubMed ID: 22174580
    [Abstract] [Full Text] [Related]

  • 26. The VALUE trial: a commentary.
    Sever P.
    J Renin Angiotensin Aldosterone Syst; 2004 Sep; 5(3):99-101. PubMed ID: 15526243
    [Abstract] [Full Text] [Related]

  • 27. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension.
    Poldermans D, Glazes R, Kargiannis S, Wernsing M, Kaczor J, Chiang YT, Yen J, Gamboa R, Fomina I.
    Clin Ther; 2007 Feb; 29(2):279-89. PubMed ID: 17472820
    [Abstract] [Full Text] [Related]

  • 28. Valsartan-amlodipine-hydrochlorothiazide: the definitive fixed combination?
    Barrios V, Escobar C.
    Expert Rev Cardiovasc Ther; 2010 Nov; 8(11):1609-18. PubMed ID: 21090936
    [Abstract] [Full Text] [Related]

  • 29. Effects of exercise therapy alone and in combination with a calcium channel blocker or an angiotensin receptor blocker in hypertensive patients.
    Ohta M, Tajiri Y, Yamato H, Ikeda M.
    Clin Exp Hypertens; 2012 Nov; 34(7):523-9. PubMed ID: 22559159
    [Abstract] [Full Text] [Related]

  • 30. Chronotherapy with valsartan/amlodipine fixed combination: improved blood pressure control of essential hypertension with bedtime dosing.
    Hermida RC, Ayala DE, Fontao MJ, Mojón A, Fernández JR.
    Chronobiol Int; 2010 Jul; 27(6):1287-303. PubMed ID: 20653455
    [Abstract] [Full Text] [Related]

  • 31. Combination angiotensin-receptor blocker (ARB)/calcium channel blocker with HCTZ vs the maximal recommended dose of an ARB with HCTZ in patients with stage 2 hypertension: the exforge as compared to losartan treatment in stage 2 systolic hypertension (EXALT) study.
    Wright RF, Duprez D, Purkayastha D, Samuel R, Ferdinand KC.
    J Clin Hypertens (Greenwich); 2011 Aug; 13(8):588-97. PubMed ID: 21806769
    [Abstract] [Full Text] [Related]

  • 32. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H, Kim-Mitsuyama S, Jinnouchi T, Matsui K, Arakawa K.
    Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
    [Abstract] [Full Text] [Related]

  • 33. Impact of supportive measures on drug adherence in patients with essential hypertension treated with valsartan: the randomized, open-label, parallel group study VALIDATE.
    Düsing R, Handrock R, Klebs S, Tousset E, Vrijens B.
    J Hypertens; 2009 Apr; 27(4):894-901. PubMed ID: 19300114
    [Abstract] [Full Text] [Related]

  • 34. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine.
    Corea L, Cardoni O, Fogari R, Innocenti P, Porcellati C, Provvidenza M, Meilenbrock S, Sullivan J, Bodin F.
    Clin Pharmacol Ther; 1996 Sep; 60(3):341-6. PubMed ID: 8841157
    [Abstract] [Full Text] [Related]

  • 35. Effects of valsartan versus amlodipine in diabetic hypertensive patients with or without previous cardiovascular disease.
    Yamashita K, Kondo T, Muramatsu T, Matsushita K, Nagahiro T, Maeda K, Shintani S, Murohara T.
    Am J Cardiol; 2013 Dec 01; 112(11):1750-6. PubMed ID: 24035165
    [Abstract] [Full Text] [Related]

  • 36. Efficacy and safety of angiotensin II type 1 receptor blocker/calcium channel blocker combination therapy for hypertension: focus on a single-pill fixed-dose combination of valsartan and amlodipine.
    Miura S, Saku K.
    J Int Med Res; 2012 Dec 01; 40(1):1-9. PubMed ID: 22429340
    [Abstract] [Full Text] [Related]

  • 37. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: An analysis of findings from the VALUE trial.
    Zanchetti A, Julius S, Kjeldsen S, McInnes GT, Hua T, Weber M, Laragh JH, Plat F, Battegay E, Calvo-Vargas C, Cieśliński A, Degaute JP, Holwerda NJ, Kobalava J, Pedersen OL, Rudyatmoko FP, Siamopoulos KC, Störset O.
    J Hypertens; 2006 Nov 01; 24(11):2163-8. PubMed ID: 17053536
    [Abstract] [Full Text] [Related]

  • 38. Amlodipine/valsartan/hydrochlorothiazide: fixed-dose combination in hypertension.
    Deeks ED.
    Am J Cardiovasc Drugs; 2009 Nov 01; 9(6):411-8. PubMed ID: 19929039
    [Abstract] [Full Text] [Related]

  • 39. Effects of combination drugs on antihypertensive medication adherence in a real-world setting: a Korean Nationwide Study.
    Kim SJ, Kwon OD, Cho B, Oh SW, Lee CM, Choi HC.
    BMJ Open; 2019 Jun 22; 9(6):e029862. PubMed ID: 31230034
    [Abstract] [Full Text] [Related]

  • 40. Chart review of patients on valsartan-based single-pill combinations vs. ARB-based free combinations for BP goal achievement.
    Chang J, Yang W, Fellers T, Kahler KH, Orloff J, Xie J, Tsaneva M, Yu AP, Wu EQ.
    Curr Med Res Opin; 2010 Sep 22; 26(9):2203-12. PubMed ID: 20673201
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 35.